At a glance
ClinicalIndex Comparison RecordN/ACompleted· 4 enrolled
Drug / intervention
Tolvaptandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Use of Tolvaptan, a Vasopressin Antagonist, to Increase Urine Dilution and Reduce Cystine Urolithiasis Among Patients With Homozygous Cystinuria: a Pilot Investigation
In Brief
A clinical study evaluating Tolvaptan for Cystinuria. Completed, enrolled 4 participants across 1 site.
Detailed Summary
The goal of this research project is to establish that in short-term use, tolvaptan is a safe and potentially effective new therapy for cystinuria, by conducting a short-term pilot study of the safety and tolerability of this drug, and assess impact on urinary stone risk parameters, among adolescent and young adult patients with clinical cystinuria.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCystinuria
CountriesUnited States
CollaboratorsOtsuka America Pharmaceutical
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedSep 2015
Enrollment StartOct 2016
Primary CompletionDec 2018
TodayJul 2026
First PostedSep 2, 2015
Enrollment StartOct 1, 2016
Primary CompletionDec 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 10.8 years ago
Interventions
Tolvaptandrug